CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned a consensus rating of “Hold” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $69.53.

Several research analysts have commented on CRSP shares. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, May 20th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Wall Street Zen raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, May 16th. The Goldman Sachs Group cut their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Finally, Barclays decreased their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research note on Friday, May 9th.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares of the company’s stock, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRSP. Allworth Financial LP boosted its stake in shares of CRISPR Therapeutics by 2,117.4% in the 4th quarter. Allworth Financial LP now owns 15,078 shares of the company’s stock valued at $593,000 after purchasing an additional 14,398 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in CRISPR Therapeutics by 10.8% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 44,692 shares of the company’s stock valued at $1,759,000 after buying an additional 4,351 shares during the period. Private Advisor Group LLC lifted its holdings in CRISPR Therapeutics by 18.5% in the fourth quarter. Private Advisor Group LLC now owns 85,036 shares of the company’s stock valued at $3,347,000 after buying an additional 13,289 shares during the period. Ipswich Investment Management Co. Inc. boosted its position in CRISPR Therapeutics by 3.1% during the fourth quarter. Ipswich Investment Management Co. Inc. now owns 25,288 shares of the company’s stock valued at $995,000 after acquiring an additional 750 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in CRISPR Therapeutics by 33.4% during the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock worth $80,000 after acquiring an additional 511 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $44.25 on Friday. The firm has a 50 day simple moving average of $38.61 and a two-hundred day simple moving average of $40.67. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $63.68. The company has a market cap of $3.82 billion, a P/E ratio of -9.79 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period last year, the firm posted ($1.43) EPS. The business’s revenue was up 71.6% on a year-over-year basis. On average, analysts expect that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.